Trial Profile
A Randomized Phase II Trial Of PS-341 And Gemcitabine In Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 30 Oct 2007 Status change
- 03 Sep 2005 New trial record.